{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:04Z","timestamp":1792788364224,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Guangdong Basic and Applied Basic Research Foundation","award":["2023A1515010360"],"award-info":[{"award-number":["2023A1515010360"]}]},{"name":"the National Natural Science Foundation of China Grant","award":["82102807"],"award-info":[{"award-number":["82102807"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China Grant","award":["82172642"],"award-info":[{"award-number":["82172642"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China Grant","award":["82373410"],"award-info":[{"award-number":["82373410"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Guangdong Province","award":["2022A1515220195"],"award-info":[{"award-number":["2022A1515220195"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-19900-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:05:57Z","timestamp":1781971557000},"page":"8931-8942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant Immunotherapy Improves Esophageal Squamous Cell Carcinoma Survival After Neoadjuvant Chemoimmunotherapy: A Multicenter Real-World Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Zhuolun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-8499","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"3","key":"19900_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"19900_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","volume":"11","author":"X Chen","year":"2023","unstructured":"Chen X, Xu X, Wang D, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. J Immunother Cancer. 2023;11(2):e005830. https:\/\/doi.org\/10.1136\/jitc-2022-005830.","journal-title":"J Immunother Cancer."},{"issue":"7","key":"19900_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41416-024-02805-5","volume":"131","author":"YY Chen","year":"2024","unstructured":"Chen YY, Wang PP, Hu Y, et al. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial. Br J Cancer. 2024;131(7):1126\u201336. https:\/\/doi.org\/10.1038\/s41416-024-02805-5.","journal-title":"Br J Cancer."},{"issue":"9","key":"19900_CR4","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30(9):2549\u201357. https:\/\/doi.org\/10.1038\/s41591-024-03064-w.","journal-title":"Nat Med."},{"issue":"10","key":"19900_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","volume":"42","author":"X Shang","year":"2024","unstructured":"Shang X, Xie Y, Yu J, et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial. Cancer Cell. 2024;42(10):1747-63.e7. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.008.","journal-title":"Cancer Cell."},{"key":"19900_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680","volume":"103","author":"X Yan","year":"2022","unstructured":"Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103:106680. https:\/\/doi.org\/10.1016\/j.ijsu.2022.106680.","journal-title":"Int J Surg."},{"issue":"3","key":"19900_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2024;167(3):838-47.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"3","key":"19900_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/JS9.0000000000000978","volume":"110","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang J, Meng H, et al. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study). Int J Surg. 2023;110(3):1430\u201340. https:\/\/doi.org\/10.1097\/JS9.0000000000000978.","journal-title":"Int J Surg."},{"issue":"6","key":"19900_CR9","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1097\/JS9.0000000000002375","volume":"111","author":"W Zhang","year":"2025","unstructured":"Zhang W, Chen X, Xue L, et al. Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: a phase 2 clinical trial. Int J Surg (Lond Engl). 2025;111(6):3831\u20137. https:\/\/doi.org\/10.1097\/JS9.0000000000002375.","journal-title":"Int J Surg (Lond Engl)."},{"issue":"13","key":"19900_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med."},{"issue":"4","key":"19900_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2023;21(4):393\u2013422. https:\/\/doi.org\/10.6004\/jnccn.2023.0019.","journal-title":"J Natl Compr Cancer Netw."},{"issue":"5","key":"19900_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2025.0220","volume":"160","author":"X Guo","year":"2025","unstructured":"Guo X, Chen C, Zhao J, et al. Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma. JAMA Surg. 2025;160(5):565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2025.0220.","journal-title":"JAMA Surg."},{"issue":"4","key":"19900_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5090\/jcs.25.024","volume":"58","author":"C Liu","year":"2025","unstructured":"Liu C, Yeh YC, Chien LI, Huang CS, Hsu HS, Hsu PK. Preliminary real-world outcomes of adjuvant immunotherapy in resected esophageal cancer: a retrospective study from Taiwan. J Chest Surg. 2025;58(4):134\u201345. https:\/\/doi.org\/10.5090\/jcs.25.024.","journal-title":"J Chest Surg."},{"key":"19900_CR14","doi-asserted-by":"publisher","first-page":"1332492","DOI":"10.3389\/fimmu.2024.1332492","volume":"15","author":"SH Xie","year":"2024","unstructured":"Xie SH, Yang LT, Zhang H, et al. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study. Front Immunol. 2024;15:1332492. https:\/\/doi.org\/10.3389\/fimmu.2024.1332492.","journal-title":"Front Immunol."},{"issue":"10","key":"19900_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110360","volume":"51","author":"M Chen","year":"2025","unstructured":"Chen M, Huang Y, Zhang R, et al. The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancer. Eur J Surg Oncol. 2025;51(10):110360. https:\/\/doi.org\/10.1016\/j.ejso.2025.110360.","journal-title":"Eur J Surg Oncol."},{"issue":"16","key":"19900_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.12354\/j.issn.1000-8179.2024.20240641","volume":"51","author":"M Zheng","year":"2024","unstructured":"Zheng M, Gan B, Wu Y. Adaptive lung cancer therapy: future perspectives. Chin J Clin Oncol. 2024;51(16):811\u20136. https:\/\/doi.org\/10.12354\/j.issn.1000-8179.2024.20240641.","journal-title":"Chin J Clin Oncol."},{"key":"19900_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2025.109383","volume":"183","author":"K Shao","year":"2025","unstructured":"Shao K, Du Y, Xu L, et al. Outcomes of neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Surgery. 2025;183:109383. https:\/\/doi.org\/10.1016\/j.surg.2025.109383.","journal-title":"Surgery."},{"issue":"1","key":"19900_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","volume":"169","author":"X Yang","year":"2025","unstructured":"Yang X, Yin H, Zhang S, et al. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2025;169(1):289-300.e6. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.06.020.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"2","key":"19900_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.111360","volume":"52","author":"J Zhu","year":"2026","unstructured":"Zhu J, Ma Y, Xiong Y, et al. Recurrence patterns and adjuvant therapy strategies in patients with esophageal squamous cell carcinoma who achieved pathological complete response after neoadjuvant immunochemotherapy: a high-volume retrospective study. Eur J Surg Oncol. 2026;52(2):111360. https:\/\/doi.org\/10.1016\/j.ejso.2025.111360.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"19900_CR20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/JS9.0000000000003546","volume":"112","author":"C Chen","year":"2026","unstructured":"Chen C, Tian Z, Lin J, et al. Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study. Int J Surg (Lond Engl). 2026;112(1):1284\u201394. https:\/\/doi.org\/10.1097\/JS9.0000000000003546.","journal-title":"Int J Surg (Lond Engl)."},{"key":"19900_CR21","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tian H, Chen X, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15:9097. https:\/\/doi.org\/10.1038\/s41467-024-52977-0.","journal-title":"Nat Commun."},{"key":"19900_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-024-01320-9","volume":"16","author":"G Ji","year":"2024","unstructured":"Ji G, Yang Q, Wang S, et al. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Med. 2024;16:49. https:\/\/doi.org\/10.1186\/s13073-024-01320-9.","journal-title":"Genome Med."},{"issue":"1","key":"19900_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1186\/s12885-023-11438-5","volume":"23","author":"S Natsuki","year":"2023","unstructured":"Natsuki S, Tanaka H, Nishiyama M, et al. Significance of CD103+ tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer. BMC Cancer. 2023;23(1):1011. https:\/\/doi.org\/10.1186\/s12885-023-11438-5.","journal-title":"BMC Cancer."},{"issue":"14","key":"19900_CR24","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.3390\/cancers15143641","volume":"15","author":"M Sakuma","year":"2023","unstructured":"Sakuma M, Mimura K, Nakajima S, et al. A potential biomarker of dynamic change in peripheral CD45RA-CD27+CD127+ central memory T cells for anti-PD-1 therapy in patients with esophageal squamous cell carcinoma. Cancers. 2023;15(14):3641. https:\/\/doi.org\/10.3390\/cancers15143641.","journal-title":"Cancers."},{"key":"19900_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2026.02.017","author":"C Yuan","year":"2026","unstructured":"Yuan C, Chen C, Liu Z, et al. Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified management. J Thorac Cardiovasc Surg. 2026. https:\/\/doi.org\/10.1016\/j.jtcvs.2026.02.017.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"8","key":"19900_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00288","volume":"8","author":"EM Lander","year":"2024","unstructured":"Lander EM, Aushev VN, Huffman BM, et al. Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response. JCO Precis Oncol. 2024;8(8):e2400288. https:\/\/doi.org\/10.1200\/PO.24.00288.","journal-title":"JCO Precis Oncol."},{"issue":"16_suppl","key":"19900_CR27","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2025.43.16_suppl.4000","volume":"43","author":"RJ Kelly","year":"2025","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577. J Clin Oncol. 2025;43(16_suppl):4000\u20134000. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4000.","journal-title":"J Clin Oncol."},{"issue":"2","key":"19900_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jtcvs.2023.12.030","volume":"168","author":"YK Yu","year":"2024","unstructured":"Yu YK, Meng FY, Wei XF, et al. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2024;168(2):417-28.e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.12.030.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"3","key":"19900_CR29","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.7150\/thno.118269","volume":"16","author":"J Song","year":"2026","unstructured":"Song J, Song X, Xie Y, Guo H, Cun Y. MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma. Theranostics. 2026;16(3):1613\u201329. https:\/\/doi.org\/10.7150\/thno.118269.","journal-title":"Theranostics."},{"issue":"1","key":"19900_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13643-025-02765-8","volume":"14","author":"M Wang","year":"2025","unstructured":"Wang M, Dong W, Wu G, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II\u2013IVa esophageal cancer: a network meta-analysis. Syst Rev. 2025;14(1):26. https:\/\/doi.org\/10.1186\/s13643-025-02765-8.","journal-title":"Syst Rev."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19900-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:51:57Z","timestamp":1789667517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19900-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["19900"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19900-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}